Biotechnology News

– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological...

STAMFORD, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...

Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises  AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing  Hamilton,...

LAS VEGAS, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Grey Cloak Tech Inc. (OTCQB: GRCK – name change pending to Healthy Extracts Inc.), a company engaged in the proprietary development of natural...

IRVINE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points...

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or...

BALA CYNWYD, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...

BRIDGEWATER, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing...

Efti clinical trial status updatesExcellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. ...